Mitogen-activated protein kinase pathway component (MAPK pathway component)

"Mitogen-activated protein kinase pathway components" refers to a broad collection of proteins and enzymes within the mitogen-activated protein kinase (MAPK) signaling pathway. The pathway includes multiple kinases (notably ERK1/2, JNK, p38, ERK5) that form hierarchical cascades regulating vital cellular processes such as proliferation, differentiation, survival, apoptosis, and stress responses[1][3][4][7]. These components are activated by extracellular stimuli like growth factors, cytokines, and environmental stressors, and mediate their effects through phosphorylation cascades[1][3][5][7]. Dysregulation of various MAPK pathway components is implicated in multiple diseases, including cancer (especially resistance and metastasis), neurodegenerative disorders, inflammatory conditions, cardiovascular diseases, and more[4][6][7]. **Key facts and rationale:** - This entry is not a specific, singular target molecule but an umbrella term for many distinct proteins (e.g., ERK1, ERK2, JNK, p38, MEK, RAF, etc.)[1][3][5][7]. - Each **individual component** (such as "Mitogen-activated protein kinase 1" for ERK2 or "p38 mitogen-activated protein kinase") qualifies as a valid therapeutic target and can have interacting drugs, mechanisms of action, and biomarkers[2][6][7]. - The plural, pathway-centric naming ("components") is **not suitable** for a canonical singular drug target entry and therefore "is_incorrect: true". **Limitations:** - Interacting drugs, mechanisms of action, and biomarkers are specific to individual members of the MAPK pathway (e.g., ERK inhibitors, JNK modulators, p38-targeted therapies), not generalizable to the entire pathway as a single target[2][4][6]. - In therapeutic research and drug development, precise identification of the specific member (e.g., ERK1, MEK1, or p38alpha) is essential. **In summary:** "Mitogen-activated protein kinase pathway components" describes a family of signal transduction proteins and enzymes, not a single, actionable therapeutic target. For structured data or actionable research, the term should be replaced with specific MAPK isoforms (e.g., Mitogen-activated protein kinase 1 (ERK2), Mitogen-activated protein kinase 14 (p38-alpha), etc.), each of which has its own pharmacology, biomarkers, and disease associations[3][7].

Other names

MAPK pathway proteinsMAPK signaling componentsMAP kinase pathway components